TSS
APUS

Two Sigma Securities’s Apimeds Pharmaceuticals US APUS Stock Holding History

Two Sigma Securities’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.9K Buy
+1,055
New +$17K ﹤0.01% 1378

Other funds holding APUS

HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Securities's APUS Position: Q1 2026 in Review

Two Sigma Securities opened a new position in Apimeds Pharmaceuticals US (APUS) in Q1 2026: 1,055 shares worth $18.9K. The stake represents ﹤0.01% of the portfolio and ranks #1378 among its holdings.

6 funds tracked by Wall St. Rank hold APUS as of Q1 2026.

  • Two Sigma Securities held 1,055 shares of Apimeds Pharmaceuticals US worth $18.9K as of Q1 2026.
  • Apimeds Pharmaceuticals US was a new Two Sigma Securities position in Q1 2026.
  • Apimeds Pharmaceuticals US made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1378 holding.
  • 6 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.